Truist Securities Downgrades Edwards Lifesciences to Hold, Lowers Price Target to $82
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has downgraded Edwards Lifesciences from Buy to Hold and lowered its price target from $110 to $82.
July 25, 2024 | 9:30 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Truist Securities has downgraded Edwards Lifesciences from Buy to Hold and lowered its price target from $110 to $82. This downgrade and significant reduction in price target could negatively impact the stock price in the short term.
The downgrade from Buy to Hold and the substantial reduction in the price target from $110 to $82 by Truist Securities is likely to be perceived negatively by investors. This could lead to a short-term decline in the stock price as market sentiment adjusts to the new rating and price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100